newsfilter
← Latest News
Business Wire·

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and